Abstract
Demyelination is a hallmark of Multiple Sclerosis (MS), and yet, few existing measures of MS currently used in the clinic are specific measures of myelination. As remyelinating therapeutics enter the clinic, indices of myelination may serve as early prognostic read outs of therapeutic efficacy. Multimodal evoked potentials (EP), neurophysiological measures of signal transduction across the central nervous system, offer several advantages over current approaches. For one, EPs offer the ability to stimulate and record from various sensory and motor modalities, allowing for assessment of deficits across multiple functional systems at once. Moreover, EPs may be more sensitive to subclinical demyelination, which may promote earlier detection and treatment of MS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
